0738 ET - The FDA approval of Vykat XR is a significant win for Soleno Therapeutics, say analysts at Stifel, who cite a very favorable and clean label and pricing that came in well above expectations. Stifel reiterates its buy rating on Soleno shares and says it thinks the drug is well positioned to launch strongly into a blockbuster opportunity, given a significant unmet need, a well-diagnosed/concentrated patient population, a favorable risk/benefit and high physician/patient awareness. Stifel, with a $74 target price on Soleno shares, says M&A remains a plausible upside case as well. Soleno surges 37% premarket to $67.22. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 27, 2025 07:38 ET (11:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.